Specifically, they focused on the synthesis and in vitro evaluation of a new TSPO ligand characterized by a substituted imidazopyridine nucleus, namely the 2-(4-(6,8-dichloro-3-(2-(dipropylamino)-2-oxoethyl)imidazo[1,2-a]pyridin-2-yl)phenoxy)acetic acid (CB235), as a high-affinity conjugatable TSPO ligand linked to the amine end-group of PAMAM dendrimers, in order to obtain a new fluorescence imaging of tumor or neurodegenerative diseases overexpressing TSPO. This evidence concerns the gene TSPO and neoplasm.